{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:12:44Z","timestamp":1774289564911,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Delaying atrial fibrillation (AF) progression is a key goal in cardiovascular treatment. However, numbers of previously published studies on delayed AF progression are relatively limited. The purpose of this study was to determine whether a cryoballoon catheter ablation (CA) strategy could delay AF progression compared to anti-arrhythmic drug (AAD) treatment in patients with paroxysmal AF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 204 subjects were enrolled in the trial, including 102 in the cryoballoon CA group and 102 in the AAD group. Participants were followed up with for 36 months. The primary study endpoint was the first occurrence of persistent atrial tachyarrhythmia, while secondary endpoints included the event rates of persistent atrial tachyarrhythmia at 1 and 2 years. The primary safety endpoint was serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, the 36-month follow-up was completed by 154 subjects (75.5%). At 3 years, documented progression from paroxysmal AF to persistent atrial tachyarrhythmia had occurred in 2 of the 102 patients assigned to undergo cryoballoon CA [2.203% (95% confidence interval (CI), 0.554\u20138.537)] and in 17 of the 102 patients assigned to receive AADs [20.223% (95% CI, 13.040\u201330.604)] [hazard ratio (HR), 0.107; 95% CI, 0.043\u20130.262; <jats:italic>P<\/jats:italic> &amp;lt; 0.001]. Lower rates of progression in the cryoballoon CA group compared to the AAD group were already obvious at 1 year [1.053% (95% CI, 0.149\u20137.238) vs. 5.284% (95% CI, 2.233\u201312.237)] [HR, 0.193; (95% CI, 0.039\u20130.956; <jats:italic>P<\/jats:italic> = 0.09)] and 2 years [2.203% (95% CI, 0.554\u20138.537) vs. 12.430% (95% CI, 7.066\u201321.371)] (HR, 0.169; 95% CI, 0.057\u20130.501, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Serious adverse events occurred in 7 of the 102 patients (6.9%) in the cryoballoon CA group and 9 of the 102 patients (8.8%) in the AAD group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cryoballoon CA was superior to AAD therapy in preventing the occurrence of persistent atrial tachyarrhythmia in patients with paroxysmal AF who had not received prior rhythm control therapy. Serious adverse events were rare.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.1003305","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:49:40Z","timestamp":1666201780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Cryoballoon catheter ablation or drug therapy to delay progression of atrial fibrillation: A single-center randomized trial"],"prefix":"10.3389","volume":"9","author":[{"given":"Jun","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuochen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/CIRCEP.112.970749","article-title":"Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry.","volume":"5","author":"Chiang","year":"2012","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/eurheartj\/ehw007","article-title":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.","volume":"37","author":"Ganesan","year":"2016","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation.","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","article-title":"Cryoablation or drug therapy for initial treatment of atrial fibrillation.","volume":"384","author":"Andrade","year":"2021","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/europace\/euab029","article-title":"Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.","volume":"23","author":"Kuniss","year":"2021","journal-title":"Europace."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ahj.2021.08.007","article-title":"Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms.","volume":"242","author":"Pavlovic","year":"2021","journal-title":"Am Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ahj.2004.09.053","article-title":"Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation.","volume":"149","author":"Kerr","year":"2005","journal-title":"Am Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.hrthm.2018.10.022","article-title":"Incidence and predictors of atrial fibrillation progression: a systematic review and meta-analysis.","volume":"16","author":"Blum","year":"2019","journal-title":"Heart Rhythm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e012554","DOI":"10.1161\/JAHA.119.012554","article-title":"Incidence and predictors of atrial fibrillation progression.","volume":"8","author":"Blum","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.hrthm.2017.01.038","article-title":"Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation.","volume":"14","author":"Padfield","year":"2017","journal-title":"Heart Rhythm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.hrthm.2014.02.018","article-title":"Long-term progression from paroxysmal to permanent atrial fibrillation following transcatheter ablation in a large single-center experience.","volume":"11","author":"Scaglione","year":"2014","journal-title":"Heart Rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacep.2015.02.018","article-title":"Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials.","volume":"1","author":"Al Halabi","year":"2015","journal-title":"JACC Clin Electrophysiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jama.2009.2029","article-title":"Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.","volume":"303","author":"Wilber","year":"2010","journal-title":"JAMA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1540-8167.2011.02137.x","article-title":"Effect of catheter ablation on progression of paroxysmal atrial fibrillation.","volume":"23","author":"Jongnarangsin","year":"2012","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/europace\/euaa298","article-title":"Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).","volume":"23","author":"Kuck","year":"2021","journal-title":"Europace."},{"key":"B18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ahj.2012.02.015","article-title":"Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy.","volume":"163","author":"De Vos","year":"2012","journal-title":"Am Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1253\/circj.68.568","article-title":"Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.","volume":"68","author":"Kato","year":"2004","journal-title":"Circ J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1378\/chest.11-0340","article-title":"A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.","volume":"141","author":"Potpara","year":"2012","journal-title":"Chest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/heartjnl-2014-307043","article-title":"Heart rate is associated with progression of atrial fibrillation, independent of rhythm.","volume":"101","author":"Holmqvist","year":"2015","journal-title":"Heart."},{"key":"B22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCEP.113.000471","article-title":"Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation.","volume":"7","author":"Takigawa","year":"2014","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2014.06.1172","article-title":"Atrial fibrillation ablation: translating basic mechanistic insights to the patient.","volume":"64","author":"Nishida","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.hrthm.2015.10.028","article-title":"Progression of atrial remodeling in patients with high-burden atrial fibrillation: implications for early ablative intervention.","volume":"13","author":"Walters","year":"2016","journal-title":"Heart Rhythm."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1003305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:49:43Z","timestamp":1666201783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.1003305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2022.1003305"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.1003305","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"article-number":"1003305"}}